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AbstrAct
Tumours arising from mesenchymal tissue components such as vascular, fibrous and adipose tissue can manifest in the 
liver. Although histopathology is often necessary for definitive diagnosis, many of these lesions exhibit characteristic 
imaging features. The radiologist plays an important role in suggesting the diagnosis, which can direct appropriate 
immunohistochemical staining at histology. The aim of this review is to present clinical and imaging findings of a 
spectrum of mesenchymal liver tumours such as haemangioma, epithelioid haemangioendothelioma, lipoma, PEComa, 
angiosarcoma, inflammatory myofibroblastic tumour, solitary fibrous tumour, leiomyoma, leiomyosarcoma, Kaposi 
sarcoma, mesenchymal hamartoma, undifferentiated embryonal sarcoma, rhabdomyosarcoma and hepatic metastases. 
Knowledge of the characteristic features of these tumours will aid in guiding the radiologic diagnosis and appropriate 
patient management.
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intrODuctiOn
Mesenchymal tumours are neoplasms that arise from vascular, 
fibrous, adipose, and other mesenchymal tissue components. 
Aside from haemangiomas, mesenchymal tumours are rela-
tively uncommon in the liver. When they do arise within 
the liver, their appearance may mimic common malignant 
neoplasms. Hence, differentiation of these rare tumours 
from more common entities is relevant to clinical practice. 
Although histopathology is often necessary for definitive 
diagnosis, many of these lesions exhibit characteristic imaging 
features. The radiologist may be the first to suggest the diag-
nosis, which can direct appropriate immunohistochemical 
staining at histology. Recognition of these tumours can direct 
management with percutaneous tissue sampling rather than 
more invasive intervention. In some cases, identification 
of typical imaging findings may even prevent unnecessary 
biopsy. In this article, we review a spectrum of common and 
uncommon mesenchymal liver tumours and their imaging 
findings.
Haemangioma
Haemangiomas are the most common mesenchymal 
liver tumour, with a reported incidence of 1–6%.1,2 
Histopathologically, haemangiomas are classified into three 
main subtypes: cavernous, capillary and sclerosing. Differ-
entiating haemangiomas from other less common tumours 
is an issue often encountered in liver imaging, particularly 
with atypical forms of haemangiomas.
Cavernous haemangioma
The most common subtype, cavernous haemangiomas 
demonstrate a characteristic appearance on imaging. On 
ultrasound, cavernous haemangiomas typically appear 
as well-defined homogenous hyperechoic lesions with 
posterior acoustic enhancement. Dynamic CT/MR shows 
peripheral globular/nodular enhancement in arterial phase, 
with an attenuation of the enhancing portions similar to 
the aorta.3 Progressive centripetal enhancement in the 
portal venous phase, and retention of contrast/“fill-in” on 
the delayed phase, are classic and also tend to follow blood 
pool.4 On T2 weighted MR images, they demonstrate high 
signal intensity, which slightly attenuates on longer TE 
T2 weighted sequences, due to inherent vascular lakes and 
channels.5 Overall, MRI has an accuracy exceeding 97%.5,6
A cavernous haemangioma greater than 5 cm is char-
acterized as a giant haemangioma. This typically has a 
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Figure 1. Haemorrhagic haemangioma: axial T2  weighted 
image demonstrates a large well-circumscribed haemangi-
oma within the right hepatic lobe with perilesional fluid com-
patible with subacute blood (arrows).
Figure 2. Flash-filling/capillary haemangioma:  axial con-
trast-enhanced T1 weighted images of a small lesion (arrow). 
Delayed phase image (a) shows persistent enhancement of 
the lesion that matches blood pool. In arterial phase (not 
shown in the figures), the lesion exhibited a rapid homog-
enous enhancement. Axial T2    weighted image (b) shows 
increased signal intensity of the lesion typical of a flash filling 
haemangioma.
Figure 3. Sclerosing haemangioma, confirmed by histology: 
axial post-contrast T1 weighted MR image in arterial (a) and 
delayed (b) phases, demonstrate a well-circumscribed lesion 
at the periphery of the right hepatic lobe (arrow) with rim 
enhancement on arterial phase and progressive incomplete 
filling on delayed phase with capsular retraction.
heterogeneous appearance due to central thrombus, myxoid 
tissue or fibrosis.7 On dynamic contrast CT/MRI, the typical early 
globular peripheral enhancement is present but complete filling 
is not seen. Its distinctive MRI appearance of high signal intensity 
on T2 weighted images and discontinuous peripheral enhance-
ment with enlargement and coalescence of the enhancing foci 
on serial post-contrast images aids in its diagnosis.7 MR images 
may show a cleft-like area and sometimes internal septa, which 
demonstrate T1-hypointensity and T2-hyperintensity.7
Haemorrhage is a rare complication of cavernous haemangi-
omas, which may occur spontaneously or after anticoagulation 
therapy. Symptoms include acute epigastric pain and vomiting. 
The diagnosis is made when the typical enhancement pattern of 
haemangioma is combined with features suggestive of intratu-
moral haemorrhage, such as high attenuation on non-contrast 
CT and high signal on T1 weighted images (Figure 1).
Capillary haemangioma
These constitute about 16% of all haemangiomas, and are typi-
cally seen in haemangiomas less than 1–2 cm in diameter—the 
“flash-filling” haemangioma.8 Dynamic CT/MRI shows rapid 
enhancement on the arterial phase (roughly equivalent to the 
aorta) with contrast retention on the venous and delayed phases 
(Figure  2). This feature allows them to be differentiated from 
hypervascular tumours (i.e. HCC, hypervascular metastases) 
which typically demonstrate contrast wash-out on the delayed 
phase.9
Sclerosing haemangioma
Haemangiomas that exhibit degeneration and fibrous replace-
ment are called sclerosed, thrombosed or hyalinized. Due to 
high fibrous content they lack the typical imaging features of a 
haemangioma, such as early peripheral enhancement, filling 
in on dynamic contrast CT/MRI and high signal intensity on 
T2  weighted images. Therefore, the prospective diagnosis of 
sclerosing haemangioma can be difficult. However, a combina-
tion of findings such as transient hepatic attenuation difference 
in the arterial phase, nodular regions of enhancement which 
are hyperintense on T2 weighted images, decrease in size over 
time, capsular retraction and the presence of additional typical 
haemangiomas may suggest the possibility of a sclerosing 
haemangioma10 (Figure 3).
Haemangiomatosis
Haemangiomatosis  is a rare condition characterized by diffuse 
replacement of the liver by haemangiomatous lesions. Haemangi-
omatosis differs from multiple or giant haemangiomas in that the 
boundary of the lesions is poorly defined. Complications include 
spontaneous rupture, thrombocytopenia and consumptive coag-
ulopathy (Kasabach–Merritt syndrome).11 On ultrasound, this 
appears as a diffuse heterogeneous hyperechoic infiltrative mass 
with hypoechoic nodules.11 On dynamic imaging, each lesion 
exhibits peripheral enhancement on the arterial phase with 
contrast retention on the delayed phase, which suggests its diag-
nosis (Figure  4). Differential diagnosis includes other vascular 
tumours such as epithelioid haemangioendothelioma (EHE) and 
angiosarcoma. Histology is generally required for confirmation.12
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Figure 4. Haemangiomatosis. Coronal T2W HASTE demon-
strates multiple haemangiomas in a patient with a known 
diagnosis of blue rubber bleb nevus syndrome.
Figure 5. Epithelioid haemangioendothelioma: contrast-en-
hanced CT in the arterial phase, showing multiple coalescent 
hypodense lesions with peripheral enhancement, more at the 
periphery of the right lobe; these were pathologically proven 
to represent EHE. EHE, epithelioid haemangioendothelioma.
Figure 6. Hepatic lipoma-gray-scale ultrasound demonstrates 
a well-circumscribed echogenic lesion with distal acoustic 
shadowing, consistent with lipoma.
Epithelioid haemangioendothelioma
Hepatic EHE is a rare tumour of vascular origin, akin to haeman-
gioma and angiosarcoma. It is a low-grade malignant tumour 
that has an intermediate clinical outcome in between that of a 
benign hepatic cavernous haemangioma and malignant angio-
sarcoma. The vascular nature of the tumour is confirmed by 
positive staining for factor III related antigen and other endothe-
lial cell markers (CD31, CD34).
Its peak incidence is between 30 and 50 years of age, and more 
commonly affects females.13,14 Extrahepatic involvement at the 
time of diagnosis may be detected in up to 36% of patients, with 
metastatic spread to lungs, lymph nodes and peritoneum being 
the most common sites.15 Recognition of EHE is important 
because it may be treated with surgical resection or transplanta-
tion even when metastatic disease is present.16
EHE usually manifests as multifocal tumours involving both 
lobes of the liver; only 13% are unifocal.15 Tumours are composed 
of multiple solid nodules in a predominantly peripheral distri-
bution, which coalesce as they enlarge, and result in capsular 
retraction. Tumour nodules have a hyperemic rim on the arterial 
phase which retains contrast on the venous phase.13
The mases are hypoechoic or heterogeneous on ultrasound. On 
CT, EHE presents as multiple peripherally located hypodense 
rim-enhancing tumours, resulting in capsular retraction in up to 
25% of patients.13 They can merge into larger confluent masses 
(Figure 5). A target pattern may be seen on contrast-enhanced 
CT or MR, characterized by a hypodense central zone, periph-
eral enhancement and a hypodense rim.13,17–19 Imaging features 
may overlap with cholangiocarcinoma or multiple metastases. 
Pasquale et al reported a distinguishing feature in a series of 11 
cases, in that none of them showed the globular enhancement 
pattern typical of haemangioma. EHE may also appear as a soli-
tary subcapsular mass with minimal or rim-like enhancement 
at early phase and progressive centripetal fill-in enhancement 
during dynamic phase imaging, as seen in some haemangi-
omas.20 EHE should be favoured over metastatic disease in cases 
of multiple peripheral subcapsular lesions that demonstrate 
increased vascularity, and result in hypertrophy of the unin-
volved liver.
Lipoma
Lipomas are rarely seen in the liver. Histologically, they consist of 
mature adipose tissue. On ultrasound, lipomas are well-circum-
scribed and homogeneously hyperechoic. They measure fat atten-
uation on CT with no enhancement on post-contrast imaging. 
On MRI, macroscopic adipose tissuedemonstratesloss of signal 
on fat-saturated pulse sequences compared with non-fat-satu-
rated pulse sequences. Microscopic adipose tissue demonstrates 
loss of signal on out-of-phase T1 weighted images compared to 
in-phase images (Figure 6).
Perivascular epithelioid cell neoplasm (PEComa)
Perivascular epithelioid cell neoplasms (PEComa) are rare 
mesenchymal tumours composed of histologically and 
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immunohistochemically distinctive “perivascular epithe-
lioid cells”, which are unusual cells with dual melanocytic and 
myxoid differentiation, typically in a perivascular distribu-
tion.21 Although the majority are benign, they can show malig-
nant features with local recurrence and distant metastases. It is 
important for radiologists to recognize the imaging findings of 
PEComas because treatment with mTOR inhibitors has shown 
promising results in malignant PEComas.22
The PEComa group of tumours includes classic angiomyolipoma 
(AML), epithelioid AML, clear-cell ‘‘sugar’’ tumours, lymphangi-
oleiomyomatosis, clear-cell myomelanocytic tumour of the falci-
form ligament/ligamentum teres, and abdominopelvic sarcoma 
of PECs. AML is relatively specific to the tuberous sclerosis 
complex (TSC), presenting in 80% of patients with tuberous scle-
rosis and in less than 0.1% of the general population.23 Hepatic 
AML is seen in about 30% tuberous sclerosis patients older than 
9 years,23 and nearly always seen concurrently with renal AML 
in TSC. Tumours comprised solely of PECs are distinguished 
from AML by names such as PEComa-NOS or simply PEComa. 
Malignant hepatic AML with metastases have been reported, but 
these tumours are usually large (greater than 15 cm).24 Addi-
tional features associated with malignant AMLs are coagulative 
necrosis, rapid growth, metastases, and loss of CD117 expression.
Imaging features of hepatic PEComas vary due to their different 
degree of adipose tissue, vessels and smooth muscle. On ultra-
sound, PEComas are often hyperechoic similar to a haeman-
gioma, but with blood flow within or at the periphery of the 
lesion. Lesions with increased smooth muscle components appear 
hypoechoic, whereas those with increased vascular components 
appear hyperechoic. CT and MRI usually demonstrate both 
the fat component and vessels25 (Figure  7). In the presence of 
decreased fat content, distinguishing this tumour from other 
hypervascular tumours such as HCC may be difficult on CT 
and MRI since fatty metamorphosis can occur in HCC.26 AMLs 
show a more prolonged enhancement in the portal phase, and 
on arterial phase about two-thirds demonstrate curved central-
ized vessels (whereas in HCC these vessels are more peripheral 
in location).25 On MRI, these central vessels are depicted as flow 
voids, and vessels coursing within the fat strongly suggest AML27 
(Figure  7). When present, ancillary features such as an early 
draining vein connecting with tumour vessels or the absence of a 
capsule may be useful in differentiating lipid-poor hepatic AML/
PEComas from hepatocellular carcinomas in a non-cirrhotic 
liver28 (Figure 8).
Angiosarcoma
Primary hepatic angiosarcoma is a rare but aggressive malignant 
vascular neoplasm. Most patients die within a year after diag-
nosis.29 Prior exposure to thorotrast, arsenic and vinyl chloride 
have been implicated as causative factors. It is noted that up to 
40% patients have underlying hepatic fibrosis and cirrhosis at 
diagnosis.29 There are four reported cases of hepatic angiosar-
coma arising from benign lesions such as haemangioendothe-
lioma and haemangioma.30,31 Multifocal involvement is typical, 
with at least 10 simultaneous lesions in the majority of patients.29 
Abnormal, pleomorphic, malignant endothelial cells are the hall-
mark of angiosarcoma, which can be rounded, polygonal or fusi-
form in shape.32 Angiosarcoma typically expresses endothelial 
markers and vascular endothelial growth factor. Immunohisto-
chemistry is therefore important in confirming the diagnosis.32
On CT wide variety of appearances may be seen in the late arte-
rial phase, such as heterogeneous, multinodular, rim-like or a 
branching pattern of enhancement. The enhancing regions show 
progressive enhancement on the portal and delayed phases. 
Angiosarcoma classically does not exhibit washout, which is 
an important distinguishing feature from multifocal HCC.29 
Individual nodules are typically circumscribed and enhancing 
(Figure  9). Diffuse “flash-fill” and “reverse haemangioma” 
centrifugal enhancement patterns have also been reported.29 
Figure 7. Angiomyolipoma: axial non-contrast (a) and con-
trast-enhanced CT (b) demonstrate a large mass involving the 
left hepatic lobe with intralesional fat (arrow in a) and heter-
ogeneous enhancement with prominent vessels (arrow in b).
Figure 8. Malignant AML (PEComa): axial contrast-enhanced 
CT (a) demonstrates a well-circumscribed 2.6 cm mass with 
fat attenuation (arrow), initially reported as probably angi-
omyolipoma. Axial contrast-enhanced CT after 3 years (b) 
demonstrates stable size and appearance of the fatty mass. 
One year later, axial contrast-enhanced CT in the arterial (c) 
and delayed phase (d) demonstrated significant increase in 
size with the formation of a hypervascular mass with washout 
mimicking HCC, this was pathologically proven as a malignant 
AML (PEComa).  AML,angiomyolipoma; HCC, hypervascular 
metastases; PEComa, perivascular epithelioid cell neoplasm.
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These multifocal tumours often contain haemorrhage resulting 
in heterogeneous appearance on MRI, with areas appearing 
hyperintense on T1WI and hypointense on T2WI. Extrahepatic 
metastases occur most commonly to the spleen, followed by 
peritoneum, pericardium, and lungs.29
Inflammatory myofibroblastic tumour
Inflammatory myofibroblastic tumour (IMT) is known by a 
variety of synonyms, such as inflammatory pseudotumour and 
plasma cell granuloma.33 It should be considered in the differ-
ential diagnosis of a solid liver lesion in the setting of systemic 
symptoms (fever, fatigue, pain and weight loss), elevated inflam-
matory markers [leukocytosis, elevated erythrocyte sedimen-
tation rate (ESR) and C-reactive protein (CRP)] and normal 
hepatic tumour markers (such as AFP, CA19-9).
Histologically, it consists of spindle cells, myofibroblasts, inflam-
matory cells and fibrous stroma. Although the exact cause is 
unknown, suggested causes include infection (i.e. EBV), vascular 
or an autoimmune process.34
The imaging features of IMT vary and are non-specific 
depending on the amount of fibrosis and cellular infiltration. It 
is solitary in more than 80% of the cases.35 On ultrasound, it can 
be hypoechoic or hyperechoic with well-defined or infiltrative 
borders and often has increased vascularity on Doppler inter-
rogation. Contrast-enhanced imaging shows various patterns of 
enhancement, including heterogeneous, homogeneous, septal 
enhancement, peripheral enhancement with delayed central 
filling, and lack of enhancement or central necrosis35 (Figure 10). 
On MRI, it is usually T1 hypointense and T2 hyperintense with 
heterogeneous enhancement.36 Since imaging findings are 
non-specific and malignancy is still a consideration, needle 
biopsy or resection is usually necessary. There are reported cases 
of shrinkage or disappearance of IMT with anti-inflammatory 
therapy.37
Solitary fibrous tumour
Solitary fibrous tumour (SFT) is a rare tumour composed of 
spindle cells and interspersed collagen. It rarely manifests in 
the liver; fewer than 100 cases have been reported, of which the 
majority were benign and 16 cases demonstrated local recurrence 
or metastases.38 Less than 5% of cases can have Doege-Potter 
syndrome which is defined as non-islet cell tumour hypogly-
cemia secondary to SFT, due to secretion of a prohormone form 
of insulin-like growth factor II.39 At histopathology, SFT is typi-
cally composed of juxtaposed hyper- and hypocellular spindle 
cell proliferation, dense collagenous stroma and numerous thin-
walled blood vessels with a staghorn configuration, a histologic 
hallmark of SFT.40 SFT can be of the cellular or fibrous variant 
per the predominant histopathology and the imaging appear-
ance varies accordingly.
At imaging, it is typically a solitary large heterogeneous mass 
marked enhancement of the periphery, mimicking other 
tumours such as sclerosing haemangioma, sclerosing and fibrol-
amellar variants of hepatocellular carcinoma (Figure  11). The 
fibrous component may show progressive enhancement similar 
Figure 9. Angiosarcoma: axial contrast-enhanced CT in arterial 
(a) and venous (b) show multiple enhancing lesions compati-
ble with angiosarcoma. The largest one exhibits enhancement 
pattern somewhat similar to haemangioma with delayed pro-
gressive enhancement—but with reversed centripetal pattern.
Figure 10. Inflammatory myofibroblastic tumour: coro-
nal reformatted image of contrast-enhanced CT images 
in a  48-year-old patient with history of Epstein-Barr virus 
demonstrates multiple bilobar masses with predominantly 
peripheral enhancement in venous phase (arrows). Delayed 
phase image (not shown) shows central enhancement of the 
masses (arrows). Axial Fluorodeoxyglucose (FDG) PET scan 
(b) shows increased FDG uptake of the masses (arrows).
Figure 11. Solitary fibrous tumour, pathologically proven: axial 
contrast-enhanced CT images show a large well defined 
hypodense lesion in the right lobe of the liver on precontrast 
CT (not shown) with marked peripheral enhancement.
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to cholangiocarcinoma. It exhibits areas of low signal intensity 
on T2 weighted images, corresponding to the fibrous component, 
which helps differentiate it from the other focal hepatic lesions, 
including cholangiocarcinoma, which is classically iso- or hyper-
intense on T2  weighted images.41 Definitive diagnosis is based 
on typical histopathology and immunohistochemistry which 
include spindle cells arranged in a storiform pattern and immu-
nohistochemical profile staining positive for CD34, vimentin, 
Bcl-2 and negative staining for actin, desmin and S-100.42
Leiomyoma
Leiomyoma is a benign smooth muscle tumour of mesenchymal 
origin. Only a few cases of primary hepatic leiomyoma have 
been reported.43 It can develop in healthy individuals but asso-
ciation with immunodeficiency and Epstein-Barr virus has been 
observed.44 Histologically, the tumour may need differentiation 
from gastrointestinal stromal tumours (GIST). On immuno-
histochemistry, leiomyomas are negative for the GIST marker 
CD117.45 On imaging, it has well-defined margins rather than 
an infiltrative pattern. On dynamic contrast-enhanced CT and 
MRI, there is intense enhancement in the arterial phase which 
persists in the portal and delayed phases without evidence of 
washout.46 Low signal on T2 weighted images aids in differenti-
ating it from a haemangioma46 (Figure 12).
Leiomyosarcoma
Primary hepatic leiomyosarcoma is rare, and most cases are 
metastases from extrahepatic sites including the gastrointestinal 
tract, uterus, retroperitoneum and lung.47 Serum markers such 
as alpha fetoprotein tend to be normal.
Pathology shows infiltrates of spindle-shaped cells with hyper-
chromatic nuclei. Immunohistochemistry is positive for desmin, 
vimentin, and SMA, but negative for keratin, S-100 protein, and 
neuron-specific enolase. Needle biopsy will allow for definitive 
diagnosis.48
CT classically demonstrates a large, marginated, heteroge-
neous hypodense mass with internal and peripheral enhance-
ment (Figure  13). A cystic mass with an enhanced thickened 
wall has also been reported, which may mimic an abscess or 
hydatid cyst.49 On MRI, it shows homogenous or heterogeneous 
hypointensity on T1    weighted  images, and hyperintensity on 
T2  weighted  images. Lack of enhancement in the arterial and 
venous phases followed by marked enhancement on the delayed 
phase has been reported and may be a useful finding.50
Kaposi sarcoma
Kaposi sarcoma is a low-grade malignancy associated with 
human herpes virus 8 (HHV-8). It is the most common intra-
hepatic neoplasm in patients with AIDS, found in 34% of AIDS 
patients at autopsy.51 It is also seen in solid organ transplant 
recipients, although rare.52
It is typically found in the perivascular areas around the 
peripheral portal branches. It consists of multiple nodules and 
shows diffuse macrovacuolar steatosis, with perinodular tissue 
featuring small vascular structures. By immunohistochemical 
detection of endothelial cell markers such as CD31 and CD34, 
Kaposi sarcoma can be differentiated from non-vascular spindle 
cell neoplasms. Detection of HHV-8 LNA-1 and D2-40 is useful 
to differentiate Kaposi sarcoma from other vascular tumours.53
On ultrasound, the liver appears heterogeneous with multiple 
hyperechoic nodules and periportal hyperechogenecity.54 CT 
shows hypoattenuating nodules which exhibit delayed enhance-
ment (Figure  14). MRI shows nodules which are hyperintense 
on T1 in-phase and hypointense on T1 out-of-phase due to the 
presence of lipid.51
Mesenchymal hamartoma
Mesenchymal hamartoma (MH) is the second most common 
benign liver tumour in children younger than 5 years. Less than 
20 cases have been reported in adults.55 Although there are 
reports of its spontaneous regression, it can potentially progress 
to an aggressive malignant undifferentiated embryonal sarcoma 
(UES). Therefore, surgical resection is the most favoured 
Figure 12. Leiomyoma: axial contrast-enhanced axial CT (a) 
shows a well-circumscribed oval-shaped enhancing mass 
within the left hepatic lobe. Axial T2  weighted (b) image 
demonstrates peripheral low signal intensity and central 
hyperintensity on T2 weighted images. This demonstrated a 
low signal intensity on T1 weighted image (not shown). This 
mass was pathologically proven to represent a benign smooth 
muscle tumour (leiomyoma).
Figure 13. Leiomyosarcoma: axial contrast-enhanced CT 
showing a large heterogeneously enhancing predominantly 
hypoattenuating mass (arrow) occupying the right hepatic 
lobe. This was pathologically proven to represent leiomyosar-
coma.
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treatment option.55 A continuum between MH and UES is 
considered since they share several common histopathologic, 
immunohistochemical, and cytogenetic features.56
MH classically consists of variable-sized cysts. Its appearance can 
vary from predominantly cystic to predominantly mesenchymal. 
Its mesenchymal components show stellate cells in a loose muco-
polysaccharide matrix surrounded by vessels and bile ducts.56
On ultrasound, the classic appearance is a complex cystic mass 
with internal septations. A complex cystic mass with septal 
and solid stromal enhancement can be seen on CT and MRI57 
(Figure 15), and high signal intensity of cystic components on 
T2 weighted images, with variable signal intensity on T1 weighted 
images due to varying internal proteinaceous components.
Undifferentiated embryonal sarcoma
UES is a rare malignant mesenchymal tumour more common in 
children, although a few cases of adult UES have been reported.58 
It is the third most common primary malignant tumour of the 
liver in childhood, after hepatoblastoma and hepatocellular 
carcinoma.59
UES consists of sarcomatous cells associated with a myxoid 
stroma. A definitive pathological diagnosis of UES is based on 
immunohistochemical analysis that is positive for CD56, CD68, 
vimentin and desmin. It is negative for hepatocyte paraffin 1 (aka 
hep par 1) and myogenin, which differentiates UES from hepato-
blastoma, HCC, and rhabdomyosarcoma (RMS), respectively.60
Discrepancy between its predominantly solid-like appear-
ance on US and cyst-like appearance on CT has been the clas-
sical description of UES.61 This may be attributable to varying 
myxoid content, which is hyperechoic on ultrasound and cystic 
Figure 14. Kaposi’s sarcoma: axial contrast-enhanced CT (a 
and c) and fused PET/CT (b and d) images demonstrate a 
small hypoattenuating lesion within segment 7 of the liver 
(arrows in a and b) and an enlarged right inguinal lymph node 
(arrows in c and d). Both the liver lesion and inguinal lymph 
node were biopsied and found to represent Kaposi’s sarcoma.
Figure 15. Mesenchymal hamartoma: gray scale US (a) shows 
complex cystic mass with solid component. Contrast CT 
image (b) shows a complex cystic appearing right hepatic 
mass, which was surgically resected and found to represent 
mesenchymal hamartoma.
Figure 16. Undifferentiated embryonal sarcoma: axial 
T2 weighted image shows a large heterogeneous mass occu-
pying the left and part of the right lobe of the liver exhibiting 
increased signal intensity with several cystic areas. Axial con-
trast-enhanced CT (not shown) demonstrated predominant 
hypoattenuation of the mass. This was pathologically proven 
to be UES. UES, undifferentiated embryonal sarcoma.
Figure 17. Rhabdomyosarcoma: axial contrast-enhanced CT 
(a) showing a large predominantly hypoattenuating mass 
occupying the left and part of the right lobe of the liver. Cor-
onal T2 weighted images (b) demonstrate the fluid-like signal 
intensity of the mass. This was pathologically proven as Rhab-
domyosarcoma.
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on CT. The solid components and septations show progressive 
enhancement at dynamic contrast CT/MRI (Figure 16). Gabor 
et al described the presence of serpentine vessels within the 
tumour on arterial phase in 10 out of 15 cases, which would be 
helpful in the diagnosis of UES when a cystic lesion with internal 
vessels is detected on CT.58 It is associated with a risk of sponta-
neous rupture which can cause hemoperitoneum and peritoneal 
seeding.62 Metastases to the lungs, pleura and peritoneum have 
been described.63,64
Rhabdomyosarcoma
RMS is a highly malignant tumour which may rarely arise in 
the biliary tree. The mean age of presentation is 3 years and it 
is rare after the first decade.65 Most patients present with jaun-
dice and fever, mimicking hepatitis.61 It commonly arises in the 
extrahepatic biliary tree, so the mass is usually adjacent to the 
porta hepatis and may grow into intrahepatic biliary system, 
invading the liver.66 It is histologically identical to sarcoma 
botryoides, commonly arising from the bladder or vagina of 
children. It therefore is at risk of being misclassified as UES. 
Distinguishing the two is important because treatment differs. 
Positive myogenin in RMS on immunohistochemistry helps in 
distinguishing it from UES.67
Ultrasound usually demonstrates biliary dilation with an intralu-
minal mass, often with associated displacement of the portal vein 
without intraluminal thrombus. CT shows a intraductal mass 
with or without biliary dilatation.68 Hypodense and heteroge-
neous tumour patterns can be seen. The pattern of enhancement 
also varies and may show different patterns including intense, 
globular, mild or even no enhancement. On MRI, it is typically a 
predominantly fluid-intensity mass which is T1 hypointense and 
T2 hyperintense69(Figure  17). Although many types of masses 
may cause biliary obstruction in children, only embryonal RMS 
arises from the biliary tree.66
Secondary mesenchymal tumours
Mesenchymal tumours may metastasize to the liver. The liver is a 
common site of metastases from leiomyosarcoma and malignant 
GIST tumours.69 Metastatic GIST tumours have imaging char-
acteristics similar to their primary tumour site. They are usually 
hyperattenuating/hyperintense, enhancing masses with necrosis, 
haemorrhage or cystic degeneration. Tumour vessels may be 
seen within the tumour70 (Figure 18).
The most common MRI appearance of metastatic leiomyo-
sarcoma is a well-defined homogenous mass with marked 
hyperintensity on T2 weighted images, similar to a hepatic 
haemangioma.71 On post-contrast imaging, it usually demon-
strates peripheral rim enhancement and central necrotic areas72 
(Figure 19).
Myxoid liposarcoma commonly metastasizes to the retroperito-
neum, bone, and soft tissues. About one-third metastases occur 
in the liver. On CT, this appears as multifocal, hypodense lesions 
with minimal peripheral enhancement.73 Fat may or may not be 
identified on imaging, depending on tumour differentiation73 
(Figure 20).
cOnclusiOn
Mesenchymal tumours of the liver vary widely in their imaging 
appearances due to the different components that comprise 
Figure 18. Metastatic GIST: axial contrast-enhanced CT shows 
multiple hypoattenuating liver metastases (arrows) in a 
57-year-old male patient with GIST. The lesions exhibit periph-
eral enhancement and central fluid attenuation. GIST, gastro-
intestinalstromal tumours.
Figure 19. Metastatic leiomyosarcoma: axial contrast-en-
hanced T1  weighted image (a) demonstrates heterogene-
ously enhancing mass (arrow) in segment V of the liver, which 
appears hypointense relative to the surrounding parenchyma. 
Axial T2  weighted image (b) demonstrates increased signal 
intensity of the mass. Surgical resection and pathological 
evaluation confirmed the diagnosis of metastasis from small 
bowel leiomyosarcoma.
Figure 20. Metastatic liposarcoma: axial contrast-enhanced 
CT shows multiple liver metastases containing fat (arrows 
in a) and a large heterogeneously enhancing predominantly 
mesenteric mass containing macroscopic fat (arrow in b), 
consistent with metastatic liposarcoma.
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